Zomedica Corp. (NYSE American:ZOM) has made a significant leadership appointment. Scott A. Jordan, with an extensive 30-year career in the life sciences and diagnostics industries, will take on the role of Executive Vice President, Finance and Chief Financial Officer starting from January 1, 2025. This move is set to play a crucial role in the company's future growth.

Zomedica's New Finance Leader Brings Vital Expertise

Scott Jordan's Background and Skills

Mr. Jordan brings a wealth of experience from his time at various companies. Prior to joining Zomedica, he was the CEO and Founder of S. Jordan Associates (SJA) in Chicago, Illinois. At SJA, he worked closely with life sciences and diagnostics companies, helping them raise non-dilutive capital and facilitating listings on public stock exchanges. He also served as the Chief Financial Officer at Inomagen Therapeutics, managing cost accounting, financial planning, and other crucial aspects. In his previous roles at Iterion Therapeutics and Salarius Pharmaceuticals, he played a key part in achieving significant milestones and getting Salarius listed on NASDAQ. His career started at Abbott Laboratories in marketing and commercialization roles.This diverse experience has equipped him with the skills and knowledge needed to drive Zomedica's growth. His expertise in organizational management, strategic finance, business development, and product commercialization will be invaluable as Zomedica looks to continue its rapid expansion in the animal health space.

Zomedica's Commitment and Growth

Zomedica is a leading veterinary health company dedicated to improving animal health. Their gold standard PulseVet® shock wave system has transformed veterinary therapeutics, and their suite of products includes the Assisi® Loop line of therapeutic devices and the TRUFORMA® diagnostic platform. With a total addressable market in the U.S. exceeding $2 billion, the company is well-positioned for growth.Under the leadership of Larry Heaton, the Chief Executive Officer, Zomedica is working to enhance the quality of care for pets, increase pet parent satisfaction, and improve the workflow, cash flow, and profitability of veterinary practices. The appointment of Scott Jordan is seen as a key step in achieving these goals.

Scott Jordan's Perspective

Scott Jordan expressed his excitement about joining Zomedica at this exciting time. "Zomedica's commitment to improving animal health through innovative solutions resonates deeply with me. I look forward to leveraging my experience to support the company's growth, deliver value to our stakeholders, and expand our impact within the veterinary healthcare market."He is confident that his skills and experience will contribute to the company's success and help it reach new heights.Zomedica is headquartered in Michigan and employs approximately 150 people. They manufacture and distribute their products from world-class facilities in Georgia and Minnesota. In 2023, the company grew revenue by 33% to $25 million and maintains a strong balance sheet with approximately $78 million in liquidity as of September 30, 2024. The company is advancing its product offerings, leveraging strategic acquisitions, and expanding internationally.It's important to note that while Zomedica is optimistic about its future, there are risks and uncertainties associated with its business. These include factors such as the outcome of clinical studies, regulatory approvals, competition, and the impact of the COVID-19 pandemic. However, the company is committed to managing these risks and continuing to grow.For more information, visit www.zomedica.com.Investor Relations Contact:Zomedica Investor Relationsinvestors@zomedica.com1-734-369-2555SOURCE: Zomedica Corp.View the original press release on accesswire.com